Targeting Obesity and MASH with a Pipeline
of Next Generation Therapeutics
MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).
OUR PROGRAMS
DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), in development for the treatment of obesity. DA-1241 is a novel, G-Protein-Coupled Receptor 119 (GPR119) agonist in development for the treatment of MASH.
recent news
Jan 01, 2025
MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
Jan 01, 2025
MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH